All In Biotech

Drug Trial Radar · NCT07132112

GT719 Injection for Moderate to Severe Refractory Autoimmune Disease

A Single-arm, Open-label Clinical Study of GT719 Injection for Moderate to Severe Refractory Autoimmune Disease

Last checked: Nov 19, 2026Latest source record: Apr 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Oct 28, 2025

Primary completion

Aug 2028

Study completion Aug 2028

Sponsor

Lead sponsor
Grit BiotechnologyIndustry
Sponsor type
Industry
Collaborators
Affiliated Hospital of Nantong University
First posted
Aug 20, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a prospective single-arm open-label clinical trial, including dose escalation and expansion phase, aims to evaluate the safety, efficacy, and cellular pharmacokinetics of GT719 Injection in patients with moderate to severe refractory autoimmune disease. A total of 30 subjects will be enrolled in this study.

Conditions

  • Auto Immune Disease

Interventions

  • GT719 InjectionBiological

    GT719 Injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants experiencing dose limiting toxicityTime frame: 28 days
  2. Incidence of treatment-emergent adverse eventsTime frame: 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Affiliated Hospital of Nantong University

    Nantong, Jiangsu, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.